An observational study in Abdominal Aortic Aneurysm and Morbid Obesity, sponsored by Aesculap AG. Not yet recruiting at 5 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Aesculap AG (part of B. Braun) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Aortic Aneurysm, Abdominal with a site in Spain — 11 open to participants now, 14 under way, none of them phase 3. Aortic Aneurysm, Abdominal · Spain.
Among the 35 studies in Aortic Aneurysm, Abdominal with a site in Spain, this one is the 18th largest by planned enrollment of the 24 observational ones that give a count, is the only one that started in 2027, is one of 24 observational ones, reaches primary completion later than 7 of the 13 other live ones, and was the 31st registered.
467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.
Browse Aortic Aneurysm, Abdominal studies →11 of the 35 studies in Aortic Aneurysm, Abdominal with a site in Spain are open now. Recruiting first, the newest first:
iVascular S.L.U. · Sites in Spain, Belgium, France and 2 more countries
Ages 55+
Instituto de Investigacion Sanitaria La Fe · Sites in Spain
Ages 18+
W.L.Gore & Associates · Sites in Spain, United States, Australia and 10 more countries
Ages 18+
Rijnstate Hospital · Sites in Spain, United States, France and 5 more countries
Ages 18+
Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd · Sites in Spain, China, Germany and 3 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2027.
This study's planned enrollment of 110 is below the median of 165 across 217 observational studies indexed under Aortic Aneurysm, Abdominal.
Median enrollment 174 across the 11 interventional studies, 201 across the 24 observational. Of the 18 that completed or were terminated, 3 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 35 have an industry lead sponsor. The 10 most frequent:
This study is registered under Aesculap AG, one of the names counted as B. Braun. Under that name alone:
Aesculap AG is the lead sponsor of 105 studies on the registry; 20 are open to participants now.
B. Braun has 1 study filed under Aortic Aneurysm, Abdominal — fewer than ten, so there is no comparison to draw.
1 of the studies in Aortic Aneurysm, Abdominal with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05378347Medtronic CardiovascularEndurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Aortic Aneurysm, Abdominal with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to describe the effectiveness of Optilene® Silver Mesh Elastic on prevention of surgical site infection (SSI) at 6 months follow-up in patients undergoing urgent laparotomy by collecting clinical data on the SSI rates, IH rates and overall clinical performance of Optilene® Silver Mesh Elastic used for the prevention of incisional hernia as prophylactic mesh in patients that require urgent median laparotomy in clinical routine.
High-risk patients according to the professional criteria (such as but not limited to: age, nutrition, body mass index, comorbidities, etc.) who are undergoing prophylactic mesh implantation to avoid surgical site infection after an emergency or urgent intra-abdominal laparotomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
These include but are not limited to:
Cholecystectomy and choledocotomy
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prophylactic mesh in high-risk patients
Device: Prophylactic mesh
Prevention of incisional hernia after a prophylactic mesh in high-risk patients
Surgical Site Infection (SSI) A2/A3 rate
SSIs remain a significant clinical problem as they are associated with substantial mortality and morbidity and impose severe demands on healthcare resources. Centers for Disease Control and Prevention Surgical Site Infection (SSI) Classification System differentiates Superficial SSI (A1), Deep Incisional SSI (A2) and Infection with involvement of organs/body cavities (A3). Only cases of A2 and A3 are considered for the Primary Outcome and are compared to rates from reference literature
Time frame: at 6 months follow-up
Cumulative rate of of postoperative complications during the study period
Numbers of all postoperative complications such as mortality, burst abdomen, bowel obstruction, bulging, necrosis, fistula, wound dehiscence, hematoma, seroma, peritonitis are added to the overall complication rate that is observed over the postoperative course
Time frame: at discharge (up to 10 days after surgery), 1 month, 6 months, 1 year and 2 year follow-up
Cumulative Surgical Site Infection (SSI) A2/A3 rate during the study period
Number of the Surgical Site Infection (SSI) (only A2 and A3) rate at every follow-up
Time frame: at 1 month, 1 year and 2 year follow-up.
Incisional hernia (IH) rate during the study period
Incisional hernia (IH) is a protrusion of tissue that forms at the site of a healing surgical scar. Incisional hernia refers to abdominal wall hernia at the site of a previous surgical incision.
Time frame: repeatedly at 6 months, 1 year and 2 year follow-up.
Length of hospital stay
Number of days the patient has to stay in hospital after the surgery
Time frame: at discharge (approximately up to 10 days after surgery)
Development of Pain: Visual Analogue Scale (VAS)
This parameter will be noted using the Visual Analogue Scale (VAS) which state "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain".
Time frame: at discharge (approximately up to 10 days after surgery), 1 month, 6 months, 1 year and 2 year follow-up, using the VAS score
Time to return to work
The number of days needed to return to work after the surgery of the individual patient is documented
Time frame: at all postoperative examinations with a single value for each individual patient
Handling of the Optilene® Silver Mesh Elastic
The handling will be evaluated using a questionnaire (Likert-type scale) with the dimensions Tensile Strength, Absence of memory effect, Elasticity, Stiffness, Surface weight, Thickness, Ease of being fixed with suture, Ease of package extraction as well as an overall opinion in five evaluation levels (excellent=1, very good=2, good=3, satisfied=4, poor=5)
Time frame: intraoperatively
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Mar 2028, 13 months later.
Of 91 observational studies under Aortic Aneurysm, Abdominal, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 13 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Sep 2026 → Feb 2027, primary completion Oct 2027 → Mar 2028 and completion Sep 2028 → Sep 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.